National
Great expectations as Congress returns from recess
As lawmakers hash out the 2010 legislative schedule for Congress, LGBT rights supporters are anticipating a House markup for the long-sought Employment Non-Discrimination Act within the next month.
Sources familiar with Capitol Hill said the House Education & Labor Committee will take up ENDA, which would bar job bias against LGBT people in the public and private workforce, shortly after lawmakers return from holiday break.
Last year, House and Senate committees held hearings on legislation that would provide workplace protections for LGBT people. The next step in both committees — the Education & Labor Committee in the House and the Health, Education, Labor & Pensions Committee in the Senate — is reporting out the legislation so floor votes can take place.
Rep. Jared Polis (D-Colo.), a gay lawmaker who serves on the House Education & Labor Committee, said he’s expecting a markup of the legislation either this month or in February and a floor vote soon after.
“Once it’s been marked up in committee, it’s simply a matter of scheduling it for the floor, and that of course depends on what else is coming to the floor, whether it’s health care or what[ever] it is, but it shouldn’t take very long,” he said.
Also expecting an ENDA markup in the House shortly is Allison Herwitt, legislative director for the Human Rights Campaign.
“We’re hopeful that it will be either January or February and we’re pushing for that,” she said.
Still, it’s unclear exactly when the House committee will take up the legislation. Aaron Albright, spokesperson for the House & Education Labor Committee, said, “nothing has been scheduled yet.”
Meanwhile, in the Senate, Jeff Merkley (D-Ore.), who sponsors ENDA in that chamber, has said the HELP Committee will take up ENDA in the spring, but Herwitt said the timing in the Senate “is a little less clear.”
“I think that we’re going to talk to [Chair Tom] Harkin’s staff people, committee staff and try to figure all of that out, what’s the timeframe that they’re looking at, how will we envision the bill moving forward in the Senate,” she said. “I mean, obviously, the Senate provides us more challenges in moving legislation, especially when it is freestanding.”
Advocates are committed to passing a version of ENDA that provides protections on the basis of sexual orientation and gender identity.
The inclusion of transgender people in ENDA has been a sensitive issue. In 2007, Rep. Barney Frank (D-Mass.) came under fire for pushing a version of ENDA that provided protections only on the basis of sexual orientation, saying at the time that Congress lacked the votes to pass an inclusive bill.
This year, the situation is different. Polis said lawmakers expect to pass “an inclusive ENDA that includes protections based on gender identity.”
Herwitt expressed similar optimism that the House would be able to pass ENDA with protections based on sexual orientation and gender identity.
“I think that we’re in a really strong place in the House,” she said. “I think that, again, when we look at our vote count for final passage, it looks good for a fully inclusive bill.”
Still, Herwitt said conversations are more nascent on the Senate side regarding ENDA and the inclusion of gender identity provisions.
“We have education that we need to do and have conversations,” she said. “I know that Sen. Merkley and his staff have been really on top of this, and having those conversations staff-to-staff — and the senator is having colleague-to-colleague conversations. And we just need to continue some of that process and then see where we are with the vote count.”
Asked whether the gender identity provisions could be a sticking point in the Senate, Herwitt replied, “I think what I’m saying is we’re still in the process of figuring all of that out. The conversations are still happening, the education process is still ongoing and obviously we want to make sure that the bill moves forward when it can move forward as a fully inclusive bill.”
Activists want DADT repeal in budget request
The repeal of “Don’t Ask, Don’t Tell,” the 1993 law that prohibits openly gay people from serving in the U.S. military, is also a primary focus for LGBT rights supporters on the Hill.
Advocates are urging President Obama to include language that would overturn the law as part of his defense budget request to Congress for the next fiscal year. The request is expected to be made public early this year.
The Servicemembers Legal Defense Network on Tuesday published a full-page ad in Roll Call newspaper calling on Obama to include repeal in his budget request. Aubrey Sarvis, executive director of the Servicemembers Legal Defense Network, writes in the letter that Obama should include repeal in his budget request to stay true to the promise he made to end the ban last year during a speech at an HRC dinner.
“There is no good reason why this White House would pass up this opportunity,” Sarvis said. “It is the logical place to get rid of the discriminatory ban. We urge the president to make good on his words on the campaign trail as well as those said last October when he emphatically declared, ‘I will end Don’t Ask, Don’t Tell.’”
Herwitt said HRC also wants Obama to include repeal of the ban on open service as part of his defense budget request.
“We have been working to make that a reality,” she said. “We are hopeful and it has been part of our plan. We think that having the White House put the policy recommendations through [the] DOD [budget request] forward is important and key.”
Whether the budget request will, in fact, include language that would repeal “Don’t Ask, Don’t Tell” remains to be seen. Shin Inouye, a White House spokesperson, wouldn’t confirm whether administration officials would include such language in the budget request.
“As we are in the midst of the policy process for the FY 2011 Budget, it would be premature to comment on its contents,” he said.
Another bill pending in Congress is the Domestic Partnership Benefits & Obligations Act. The legislation — approved late last year by both House and Senate committees — would allow the same-sex partners of LGBT federal workers to receive the same benefits as the spouses of straight workers, including health and pension benefits.
But the timing for a floor vote is not yet clear. Herwitt said she doesn’t know when floor votes would take place and said HRC is “working with our allies in the House and the Senate to try and figure out what is the schedule, what are they looking at.”
Sen. Joseph Lieberman (I-Conn.), the sponsor of the bill in that chamber, said last month a floor vote wouldn’t take place until lawmakers receive cost offset information from the U.S. Office of Personnel Management for implementing the measure within the agency’s existing budget.
Leslie Phillips, spokesperson for the Senate Homeland Security & Governmental Affairs Committee, which has jurisdiction over the legislation, said Tuesday that lawmakers have “not yet received the offset information from OPM.” The agency didn’t respond to DC Agenda’s request for comment.
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
Holiday week brings setbacks for Trump-Vance trans agenda
Your guide to D.C.’s queer New Year’s Eve parties
Long-awaited ‘Pillion’ surpasses the sexy buzz
Reasons to be optimistic about 2026
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Using movement to boost your mental health during holidays
